The promise of nuclear fusion feels simple. Just as stars fuse hydrogen into heavier elements to produce energy, a fusion reactor generates massive amounts of energy by combining lightweight particles ...

Oracle is introducing its latest updates to Oracle AI Agent Studio for Fusion Applications, a comprehensive platform for building, testing, and deploying AI agents and agent teams across the ...

The fusion energy landscape is evolving rapidly. Once confined to experimental research, fusion is now emerging as a strategic national priority for research and development. The IAEA World Fusion ...

Most people with HCM can participate in mild- to moderate-intensity exercise safely. When it comes to vigorous exercise and competitive sports, there may be a need for additional guidance from your ...

Oracle Corp.’s NetSuite subsidiary today announced a major overhaul of its cloud enterprise resource planning suite at its SuiteWorld conference, introducing NetSuite Next, a new version of the ...

BENGALURU, India, Oct. 3, 2025 /PRNewswire/ -- Infosys (INFY) (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced its ...

DALLAS, Sept. 30, 2025 /PRNewswire/ --Intellinum™, a global leader in Oracle-powered supply chain and logistics innovation, today announced the launch of Fusion AI Agents across its AI ...

MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...

Oracle yesterday announced more than a dozen AI agents that will be available as part of its Fusion HCM application, complementing the twelve already announced earlier this year, along with many ...

AUSTIN, Texas, Sept. 16, 2025 /PRNewswire/ -- Oracle has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Oracle Fusion Cloud Human ...

MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...

Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. We conducted a phase 3, ...